Anixa Biosciences, Inc.ANIXNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P56
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q1 2026 | -6.92% |
| Q4 2025 | 25.56% |
| Q3 2025 | -17.85% |
| Q2 2025 | -8.34% |
| Q1 2025 | 8.71% |
| Q4 2024 | 1.20% |
| Q3 2024 | 0.00% |
| Q2 2024 | -25.81% |
| Q1 2024 | 56.48% |
| Q4 2023 | -18.22% |
| Q3 2023 | 9.00% |
| Q2 2023 | 8.27% |
| Q1 2023 | -22.66% |
| Q4 2022 | 42.31% |
| Q3 2022 | -27.08% |
| Q2 2022 | -9.21% |
| Q1 2022 | 7.26% |
| Q4 2021 | -14.31% |
| Q3 2021 | 56.99% |
| Q2 2021 | -7.69% |
| Q1 2021 | 162.48% |
| Q4 2020 | -62.96% |
| Q3 2020 | 9.39% |
| Q2 2020 | 26.51% |
| Q1 2020 | -9.40% |
| Q4 2019 | 18.97% |
| Q3 2019 | -17.55% |
| Q2 2019 | -37.96% |
| Q1 2019 | -10.51% |
| Q4 2018 | -14.59% |
| Q3 2018 | 197.52% |
| Q2 2018 | -8.21% |
| Q1 2018 | -26.31% |
| Q4 2017 | -10.89% |
| Q3 2017 | 115.58% |
| Q2 2017 | -18.67% |
| Q1 2017 | 244.16% |
| Q4 2016 | -164.60% |
| Q3 2016 | -12.20% |
| Q2 2016 | -21.02% |